{"id":27,"date":"2022-12-14T21:38:52","date_gmt":"2022-12-14T21:38:52","guid":{"rendered":"https:\/\/mpsdsehcp-dev-001.azurewebsites.net\/en\/mucopolysaccharidosis-mps\/?page_id=27"},"modified":"2023-12-04T09:14:15","modified_gmt":"2023-12-04T09:14:15","slug":"managing-mps","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-gb\/mps\/managing-mps\/","title":{"rendered":"Managing MPS"},"content":{"rendered":"
Coordinated care for your patients: driving optimal outcomes in MPS management<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n
Decades of ongoing research and clinical experience have produced a new era in the optimal management of mucopolysaccharidosis (MPS) disorders. This rapidly evolving standard of care for MPS relies on the geneticist at the centre of a healthcare delivery model that embodies coordinated, multidisciplinary care and provides physicians unmatched opportunities to change patients\u2019 lives.1\u20133<\/sup><\/p>\n Optimising patient outcomes requires coordinated care.1\u20133<\/sup><\/strong><\/p>\n <\/div>\n \n The heterogeneous and variable nature of MPS disorders necessitates a personalised approach to coordinated patient care.4<\/sup> The aim of coordinated care is to help patients achieve a greater quality of life, which includes:<\/p>\n For paediatric patients with chronic, complex, multisystemic genetic diseases such as MPS, care through a coordinated approach is associated with reduction in healthcare utilisation and improved health outcomes.5\u20138<\/sup><\/p>\n Prompt diagnosis and comprehensive multisystemic baseline evaluation at diagnosis and prior to enzyme replacement therapy (ERT) with a coordinated team are critical first steps toward establishing an individualised management plan.1<\/sup><\/p>\n Coordination must be implemented across all elements of the broader healthcare system (e.g. speciality care, hospitals, home healthcare and community services) and within patients\u2019 individualised management plans.3<\/sup> Your role can be essential to the implementation of best practices in the management of MPS disorders and improvement of patient outcomes.<\/p>\n To address the underlying cause and multisystemic complications of MPS, management guidelines for certain MPS sub-types call for a coordinated approach consisting of a team of specialists anchored by a geneticist or metabolic physician.<\/p>\n <\/div>\n\n In the new era of MPS, the many aspects of disease management may be grouped into three pillars of care designed to optimise patient outcomes.<\/strong><\/p>\n Application of optimal MPS disease management, grouped into the following three pillars of care, can help to improve patient outcomes:<\/p>\n The new era of management for progressive, complex, genetic conditions, such as mucopolysaccharidosis (MPS) disorders, hinges on the efficient coordination of each patient\u2019s healthcare team.1<\/sup><\/p>\n Geneticists and\/or metabolic specialists are typically at the centre and help to coordinate multidisciplinary care and an individualised management plan.3,4<\/sup><\/p>\n In patients with MPS disorders, the benefits of coordinated care may improve many aspects of a patient\u2019s, and a family\u2019s, outlook over the long term.3,4<\/sup><\/strong><\/p>\n Many MPS disorders have available management guidelines and speciality-specific consensus recommendations regarding lifetime management of MPS. Guidelines typically recommend the following:3,4<\/sup><\/p>\n Early and ongoing assessments from a coordinated-care team can improve patient outcomes and may help prevent irreversible damage.4<\/sup><\/p>\n Adapted from Hendriksz, Am I Med Genet Part A, 2014.<\/em> Abbreviations: 6MWT, 6-minute walk test; CT, computed tomography; ERT, enzyme replacement therapy; FVC, forced vital capacity; MRI, magnetic resonance imaging; MVV, maximum voluntary ventilation; QoL, quality of life.<\/small><\/p>\n<\/figcaption>\n <\/figure>\n Frequency of assessments and involvement of specific specialists vary across the different MPS types. For patients with MPS diseases associated with primary neurodegenerative and cognitive complications, such as MPS I, II, and III, additional and regular neurobehavioural and psychiatric evaluations are recommended.4-6<\/sup><\/p>\n In addition to speciality-specific assessments that should be done to facilitate positive long-term outcomes for patients with MPS, important steps can be taken by the coordinating physician, typically the geneticist and\/or metabolic specialist, related to general health. Their role in educating other healthcare professionals (e.g. dentists, physiotherapists, paediatricians, family doctors) and families about the disease and general management strategies is critical and should include the following:3<\/sup><\/p>\n <\/div>\n <\/figure>\n <\/div>\n \t\t<\/div>\n\t<\/div>\n<\/div>\n\n
Facilitating efficient coordination of clinicians across specialities3<\/sup><\/h3>\n
\n
<\/div>\n <\/figure>\n <\/div>\n <\/div>\n<\/div>\n\n
Progress and promise through three pillars of care<\/h3>\n
\n
<\/div>\n <\/figure>\n <\/div>\n \t\t<\/div>\n\t<\/div>\n<\/div>\n\n
\n
Lifetime management in the new era of MPS<\/h3>\n
\n
Ongoing multisystemic assessments in patients with Morquio A3<\/sup><\/h3>\n \n \n \n \n
<\/div>\n
\n
\n
\n